Biocon Biologics on Tuesday announced a global collaboration agreement with Voluntis to develop and distribute digital therapeutics supporting people with diabetes on biologics therapy. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement. "The demand for at-home treatment and telemedicine solutions …
